The CAR-T field was truly energized when Carl June and colleagues at the University of Pennsylvania, using second generation CD19-specific CAR-T cells, achieved two complete responses in the treatment of three patients with refractory advanced chronic lymphocytic leukemia (CLL) using anti-CD19 CAR T cells (4, 35). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.